Grifols Earnings Calls
Release date | May 12, 2025 |
EPS estimate | $0.140 |
EPS actual | $0.100 |
EPS Surprise | -28.57% |
Revenue estimate | 1.731B |
Revenue actual | 1.993B |
Revenue Surprise | 15.19% |
Release date | Mar 06, 2025 |
EPS estimate | $0.130 |
EPS actual | $0.260 |
EPS Surprise | 100.00% |
Revenue estimate | 1.921B |
Revenue actual | 2.046B |
Revenue Surprise | 6.49% |
Release date | Nov 07, 2024 |
EPS estimate | $0.220 |
EPS actual | $0.160 |
EPS Surprise | -27.27% |
Revenue estimate | 2.03B |
Revenue actual | 1.966B |
Revenue Surprise | -3.15% |
Release date | Jul 30, 2024 |
EPS estimate | $0.230 |
EPS actual | $0.0200 |
EPS Surprise | -91.30% |
Revenue estimate | 1.88B |
Revenue actual | 1.955B |
Revenue Surprise | 3.96% |
Last 4 Quarters for Grifols
Below you can see how GRFS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Release date | Jul 30, 2024 |
Price on release | $7.75 |
EPS estimate | $0.230 |
EPS actual | $0.0200 |
EPS surprise | -91.30% |
Date | Price |
---|---|
Jul 24, 2024 | $7.73 |
Jul 25, 2024 | $7.78 |
Jul 26, 2024 | $7.74 |
Jul 29, 2024 | $7.71 |
Jul 30, 2024 | $7.75 |
Jul 31, 2024 | $7.47 |
Aug 01, 2024 | $7.64 |
Aug 02, 2024 | $7.58 |
Aug 05, 2024 | $7.27 |
4 days before | 0.259% |
4 days after | -6.19% |
On release day | -3.61% |
Change in period | -5.95% |
Release date | Nov 07, 2024 |
Price on release | $9.50 |
EPS estimate | $0.220 |
EPS actual | $0.160 |
EPS surprise | -27.27% |
Date | Price |
---|---|
Nov 01, 2024 | $8.84 |
Nov 04, 2024 | $8.80 |
Nov 05, 2024 | $9.29 |
Nov 06, 2024 | $9.05 |
Nov 07, 2024 | $9.50 |
Nov 08, 2024 | $9.49 |
Nov 11, 2024 | $9.32 |
Nov 12, 2024 | $9.10 |
Nov 13, 2024 | $9.09 |
4 days before | 7.47% |
4 days after | -4.32% |
On release day | -0.105% |
Change in period | 2.83% |
Release date | Mar 06, 2025 |
Price on release | $8.50 |
EPS estimate | $0.130 |
EPS actual | $0.260 |
EPS surprise | 100.00% |
Date | Price |
---|---|
Feb 28, 2025 | $8.44 |
Mar 03, 2025 | $8.58 |
Mar 04, 2025 | $8.27 |
Mar 05, 2025 | $8.71 |
Mar 06, 2025 | $8.50 |
Mar 07, 2025 | $8.43 |
Mar 10, 2025 | $7.80 |
Mar 11, 2025 | $7.73 |
Mar 12, 2025 | $7.76 |
4 days before | 0.711% |
4 days after | -8.71% |
On release day | -0.82% |
Change in period | -8.06% |
Release date | May 12, 2025 |
Price on release | $7.73 |
EPS estimate | $0.140 |
EPS actual | $0.100 |
EPS surprise | -28.57% |
Date | Price |
---|---|
May 06, 2025 | $7.22 |
May 07, 2025 | $7.32 |
May 08, 2025 | $7.30 |
May 09, 2025 | $7.10 |
May 12, 2025 | $7.73 |
May 13, 2025 | $7.86 |
May 14, 2025 | $7.57 |
May 15, 2025 | $7.85 |
May 16, 2025 | $7.76 |
4 days before | 7.06% |
4 days after | 0.388% |
On release day | 1.68% |
Change in period | 7.48% |
Grifols Earnings Call Transcript Summary of Q1 2025
Grifols Q1 2025 Earnings Call Summary for Investors
1. Strong Performance Metrics:
- Q1 2025 revenue reached €1.786 billion, reflecting a 7.4% increase on a constant currency basis and a 10% increase on a like-for-like basis.
- Adjusted EBITDA was €400 million, up 14.2% year-on-year at constant currency, with a like-for-like growth of nearly 22%.
- There was a negative free cash flow of €44 million for the quarter primarily due to a one-time payment to ImmunoTek, but this represents a year-on-year improvement of more than €200 million.
- The company plans for further growth throughout 2025, forecasting sustained revenue increases, particularly in its immunoglobulin franchise.
2. Key Business Drivers:
- The immunoglobulin (IG) franchise grew by 17.5%, with strong performance in both intravenous (IVIG) and subcutaneous IG, the latter seeing a remarkable 91% increase in the first quarter.
- The biopharma segment remains a significant growth driver, despite some temporary challenges with albumin and rabies.
3. Strategic Response to Market Conditions:
- Grifols is monitoring macroeconomic factors, including U.S. drug pricing policies and tariffs, asserting confidence in its strategic positioning and operational capabilities to navigate these challenges.
- The company has maintained a diversified global footprint through plasma donor centers and manufacturing facilities, mitigating risks from geopolitical tensions and market fluctuations.
4. Operational Improvements:
- Consistent focus on cost efficiencies and operational excellence, with ongoing initiatives expected to lead to improvements in gross margins and EBITDA margins throughout the year.
- Advances in plasma processing capabilities expected to enhance inventory costs and profitability.
5. Adjusted Guidance:
- While the company has not raised its 2025 guidance despite strong Q1 performance, it remains optimistic about sustaining growth. The leadership cites caution amid the changing macroeconomic landscape as a reason for maintaining existing forecasts.
6. Capital Allocation and Investment Plans:
- Grifols is committed to deleveraging, achieving a slight decrease in leverage ratios to below 4.5 times due to improved cash flow generation.
- Investment in Canadian operations and partnerships in emerging markets aims to bolster local manufacturing and supply capabilities.
7. Pipeline Innovations:
- The company anticipates the launch of fibrinogen therapy in Q4 2025 in Europe, with plans for U.S. approval in 2026, positioning Grifols for further growth in specialty products.
Conclusion:
Grifols is exhibiting strong operational performance and strategic resilience amidst a challenging market backdrop. Investors should note the company's positive growth trajectory in the biopharma sector, particularly its robust immunoglobulin sales. However, caution remains regarding external market influences, which may necessitate prudent financial management and strategic flexibility moving forward.